Evidence map›Paper›PMID 33558481›Full record

ArticleCell death & disease2021

SPRTN protease-cleaved MRE11 decreases DNA repair and radiosensitises cancer cells.

Juri Na, Joseph A Newman, Chee Kin Then, Junetha Syed, Iolanda Vendrell, Ignacio Torrecilla, Sophie Ellermann, Kristijan Ramadan, Roman Fischer, Anne E Kiltie

Open access · goldAbstract read
In one paragraph

Article in Cell death & disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Juri NaMRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, OX3 7DQ, UK.
Joseph A NewmanCentre for Medicines Discovery, University of Oxford, Oxford, UK.
Chee Kin ThenMRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, OX3 7DQ, UK.
Junetha SyedMRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, OX3 7DQ, UK.
Iolanda VendrellMRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, OX3 7DQ, UK.
Ignacio TorrecillaMRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, OX3 7DQ, UK.ORCID 0000-0003-4283-0283
Sophie EllermannMRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, OX3 7DQ, UK.ORCID 0000-0002-1598-8344
Kristijan RamadanMRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, OX3 7DQ, UK.ORCID 0000-0001-5522-021X
Roman FischerTarget Discovery Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Anne E KiltieMRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, OX3 7DQ, UK. anne.kiltie@oncology.ox.ac.uk.ORCID 0000-0001-7208-2912
University of Oxford · GB

Funding

Cancer Research UK 23279Cancer Research UK C5255/A23755Medical Research Council MC_EX_MR/K022830/1Medical Research Council MC_PC_12001/1Medical Research Council MC_UU_00001/1Wellcome Trust 211944/Z/18/Z
6 · The paper itself

Abstract

The human MRE11/RAD50/NBS1 (MRN) complex plays a crucial role in sensing and repairing DNA DSB. MRE11 possesses dual 3'-5' exonuclease and endonuclease activity and forms the core of the multifunctional MRN complex. We previously identified a C-terminally truncated form of MRE11 (TR-MRE11) associated with post-translational MRE11 degradation. Here we identified SPRTN as the essential protease for the formation of TR-MRE11 and characterised the role of this MRE11 form in its DNA damage response (DDR). Using tandem mass spectrometry and site-directed mutagenesis, the SPRTN-dependent cleavage site for MRE11 was identified between 559 and 580 amino acids. Despite the intact interaction of TR-MRE11 with its constitutive core complex proteins RAD50 and NBS1, both nuclease activities of truncated MRE11 were dramatically reduced due to its deficient binding to DNA. Furthermore, lack of the MRE11 C-terminal decreased HR repair efficiency, very likely due to abolished recruitment of TR-MRE11 to the sites of DNA damage, which consequently led to increased cellular radiosensitivity. The presence of this DNA repair-defective TR-MRE11 could explain our previous finding that the high MRE11 protein expression by immunohistochemistry correlates with improved survival following radical radiotherapy in bladder cancer patients.

Indexed as

DNA DamageDNA RepairRadiation ToleranceAcid Anhydride HydrolasesCell Cycle ProteinsCell Line, TumorCell ProliferationDNA-Binding ProteinsG2 Phase Cell Cycle CheckpointsHEK293 CellsHumansMRE11 Homologue ProteinNuclear ProteinsProteolysisSubstrate SpecificityUrinary Bladder NeoplasmsAcid Anhydride HydrolasesCell Cycle ProteinsDNA-Binding ProteinsMRE11 Homologue ProteinMRE11 protein, humanNBN protein, humanNuclear ProteinsRAD50 protein, humanSPRTN protein, human

Identifiers

PMID33558481
PMCPMC7870818
OpenAlexW3126086342

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.